Bispecific Antibodies Engineered to be Pumped into Disease Tissue for Ultra-Low Dose Therapeutic Efficacy

Time: 11:15 am
day: Track B - Day 1 AM


– Outlining how antibodies rely on passive transport mechanisms to reach their targets
– Understanding barriers can hinder tissue entry enough to limit targeting/efficacy, even at high, near toxic doses
– Caveolae pump engineered bispecific antibodies across endothelium to block key targets inside diseased lung
– Discussing how active immunodelivery system improves precision lung tissue penetration enough to boost therapeutic potency >1000-fold